IntegraGen Reports Sales of 4.8 M€ for the First Half of 2021, a 2% Increase Versus 2020, and a Cash Position of 4.3 M€
16 Juillet 2021 - 7:30AM
Business Wire
- Slight revenue growth despite the impact of the pandemic during
the first half of the year.
- Strong increase in order intake sets the stage for an
anticipated dynamic growth during the second half of the 2021.
Regulatory News:
IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), a
company specializing in decoding the human genome which performs
interpretable genomic analyzes for academic and private
laboratories, today announced its unaudited turnover for the first
half of 2021.
The unaudited first half turnover amounted to 4,816 k€, up 2%
compared to the first half of 2020 (4,706 k€). This growth was
achieved despite the sharp slowdown in general economic activity
during the first half of 2021 compared with H1 2020, whose first
quarter was less affected by the pandemic. This sustained growth
demonstrates the robustness of IntegraGen's business model.
R&D sequencing activities continued to progress at a
moderate pace, driven by whole genome sequencing projects performed
for the European customers. While sequencing activities associated
with the external platforms operated by IntegraGen benefited from
the demand of sequencing projects linked to the pandemic,
oncology-related clinical research activities, in particular the
sales of interpretation software, slowed significantly for the same
reason.
The company’s cash position at the end of June 2021 was 4,272
k€, a decrease of nearly 850 k€ compared to the cash position as of
December 31, 2020. This variation was due to change in working
capital requirements and investments, particularly in the company’s
quality systems to obtain several certifications which will lead to
increase revenues generated from customers in regulated
industries.
Finally, the orders booked as of June 30, 2021 were
significantly higher compared to the same period of 2020, setting
the stage for a sustained growth in activities during the second
half of 2021. The integration of IntegraGen into the OncoDNA Group,
which acquired a majority of the company's shares in 2020 through a
friendly takeover bid, also enhances the prospects for IntegraGen's
additional sales growth as a result of the ability to leverage the
Group's subsidiaries and distributors.
Bernard Courtieu, CEO of IntegraGen, said: “The business
we generated during the first half of 2021 confirms that despite
the ongoing pandemic that continues to disrupt our activities, the
trajectory of our revenue growth is sustainable, albeit at a lower
level, with prospects for a significant recovery. The acquisition
of a majority of the company's shares by the Belgian company
OncoDNA results in commercial and operational synergies which will
enable IntegraGen to continue its development and growth as a vital
part of the OncoDNA Group."
The financial results for the first half of 2021 will be
published on October 8, 2021.
About IntegraGen
IntegraGen is an OncoDNA group company specializing in the
genomics of cancer and rare genetic diseases. Backed by highly
competent and qualified teams, IntegraGen is a leading player in
DNA sequencing services and genomic data interpretation software.
The company runs one of the largest NGS labs in France and operates
for research institutes of excellence. As part of OncoDNA group,
IntegraGen leverages the power of next generation sequencing with
the mission of delivering the promise of precision medicine to
patients. IntegraGen has about 50 employees and generated €9
million of revenue in 2020. Based in France, IntegraGen is also
present in the United States and is part of the OncoDNA group which
works with an international network of 35 distributors. The Group
also provides biomarker testing and clinical interpretation tools
to guide treatment and monitoring of late stage solid tumors and
accelerate the development of new cancer drugs.
IntegraGen is listed on Euronext Growth in Paris (ISIN:
FR0010908723 - Mnemo: ALINT - Eligible PEA-PME).
For further information, visit www.integragen.com and connect
with us on LinkedIn or Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210715006030/en/
IntegraGen Bernard COURTIEU CEO Pierre FLAMANT CFO
contact@integragen.com +33 (0)1 60 91 09 00
NewCap Investor and Media Relations Louis-Victor
DELOUVRIER integragen@newcap.eu +33 (0)1 44 71 98 53
Integragen (EU:ALINT)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Integragen (EU:ALINT)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024